Brentjens, R.J. et al. CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia. Sci. Transl. Med. 5, 177ra38 (2013).
Grupp, S.A. et al. Chimeric-antigen-receptor-modified T cells for acute lymphoid leukemia. N. Engl. J. Med. 368, 1509–1518 (2013).
Maude, S.L. et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N. Engl. J. Med. 371, 1507–1517 (2014).
Lee, D.W. et al. T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukemia in children and young adults: a phase 1 dose-escalation trial. Lancet 385, 517–528 (2015).
Davila, M.L. et al. Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia. Sci. Transl. Med. 6, 224ra25 (2014).
Porter, D.L. et al. Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia. Sci. Transl. Med. 7, 303ra139 (2015).
Kochenderfer, J.N. et al. B cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells. Blood 119, 2709–2720 (2012).
Till, B.G. et al. CD20-specific adoptive immunotherapy for lymphoma using a chimeric antigen receptor with both CD28 and 4-1BB domains: pilot clinical trial results. Blood 119, 3940–3950 (2012).
Ahmed, N. et al. Human epidermal growth factor receptor 2 (HER2)-specific chimeric antigen receptor-modified T cells for the immunotherapy of HER2-positive sarcoma. J. Clin. Oncol. 33, 1688–1696 (2015).
Kershaw, M.H. et al. A phase 1 study on adoptive immunotherapy using gene-modified T cells for ovarian cancer. Clin. Cancer Res. 12, 6106–6115 (2006).
Pule, M.A. et al. Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma. Nat. Med. 14, 1264–1270 (2008).
Kershaw, M.H., Westwood, J.A. & Darcy, P.K. Gene-engineered T cells for cancer therapy. Nat. Rev. Cancer 13, 525–541 (2013).
Kowolik, C.M. et al. CD28 co-stimulation provided through a CD19-specific chimeric antigen receptor enhances in vivo persistence and antitumor efficacy of adoptively transferred T cells. Cancer Res. 66, 10995–11004 (2006).
Brentjens, R.J. et al. Genetically targeted T cells eradicate systemic acute lymphoblastic leukemia xenografts. Clin. Cancer Res. 13, 5426–5435 (2007).
Stephan, M.T. et al. T cell–encoded CD80 and 4-1BBL induce auto- and trans-co-stimulation, resulting in potent tumor rejection. Nat. Med. 13, 1440–1449 (2007).
Milone, M.C. et al. Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic efficacy in vivo. Mol. Ther. 17, 1453–1464 (2009).
Savoldo, B. et al. CD28 co-stimulation improves expansion and persistence of chimeric-antigen-receptor-modified T cells in lymphoma patients. J. Clin. Invest. 121, 1822–1826 (2011).
Lim, W.A. & June, C.H. The principles of engineering immune cells to treat cancer. Cell 168, 724–740 (2017).
Rochman, Y., Spolski, R. & Leonard, W.J. New insights into the regulation of T cells by γc family cytokines. Nat. Rev. Immunol. 9, 480–490 (2009).
Zeng, R. et al. The molecular basis of IL-21-mediated proliferation. Blood 109, 4135–4142 (2007).
Hinrichs, C.S. et al. IL-2 and IL-21 confer opposing differentiation programs to CD8+ T cells for adoptive immunotherapy. Blood 111, 5326–5333 (2008).
Xin, G. et al. A critical role of IL-21-induced BATF in sustaining CD8 T cell–mediated chronic viral control. Cell Rep. 13, 1118–1124 (2015).
Zeng, R. et al. Synergy of IL-21 and IL-15 in regulating CD8+ T cell expansion and function. J. Exp. Med. 201, 139–148 (2005).
Markley, J.C. & Sadelain, M. IL-7 and IL-21 are superior to IL-2 and IL-15 in promoting human T cell–mediated rejection of systemic lymphoma in immunodeficient mice. Blood 115, 3508–3519 (2010).
Quintarelli, C. et al. Coexpression of cytokine and suicide genes to enhance the activity and safety of tumor-specific cytotoxic T lymphocytes. Blood 110, 2793–2802 (2007).
Pegram, H.J. et al. Tumor-targeted T cells modified to secrete IL-12 eradicate systemic tumors without need for prior conditioning. Blood 119, 4133–4141 (2012).
Hsu, C. et al. Cytokine-independent growth and clonal expansion of a primary human CD8+ T cell clone following retroviral transduction with the IL15 gene. Blood 109, 5168–5177 (2007).
Zhang, L. et al. Tumor-infiltrating lymphocytes genetically engineered with an inducible gene encoding interleukin-12 for the immunotherapy of metastatic melanoma. Clin. Cancer Res. 21, 2278–2288 (2015).
Stahl, N. et al. Choice of STATs and other substrates specified by modular tyrosine-based motifs in cytokine receptors. Science 267, 1349–1353 (1995).
Nicholson, I.C. et al. Construction and characterization of a functional CD19-specific single chain Fv fragment for immunotherapy of B lineage leukemia and lymphoma. Mol. Immunol. 34, 1157–1165 (1997).
Gattinoni, L. et al. A human memory T cell subset with stem-cell-like properties. Nat. Med. 17, 1290–1297 (2011).
Marzec, M. et al. Oncogenic kinase NPM–ALK induces through STAT3 expression of immunosuppressive protein CD274 (PD-L1, B7-H1). Proc. Natl. Acad. Sci. USA 105, 20852–20857 (2008).
Lastwika, K.J. et al. Control of PD-L1 expression by oncogenic activation of the AKT-mTOR pathway in non-small-cell lung cancer. Cancer Res. 76, 227–238 (2016).
Eyquem, J. et al. Targeting a CAR to the TRAC locus with CRISPR–Cas9 enhances tumor rejection. Nature 543, 113–117 (2017).
Cherkassky, L. et al. Human CAR-T cells with cell-intrinsic PD-1 checkpoint blockade resist tumor-mediated inhibition. J. Clin. Invest. 126, 3130–3144 (2016).
Sabatino, M. et al. Generation of clinical-grade CD19-specific CAR-modified CD8+ memory stem cells for the treatment of human B cell malignancies. Blood 128, 519–528 (2016).
Cieri, N. et al. IL-7 and IL-15 instruct the generation of human memory stem T cells from naive precursors. Blood 121, 573–584 (2013).
Cui, W., Liu, Y., Weinstein, J.S., Craft, J. & Kaech, S.M. An interleukin-21–interleukin-10–STAT3 pathway is critical for functional maturation of memory CD8+ T cells. Immunity 35, 792–805 (2011).
Siegel, A.M. et al. A critical role for STAT3 transcription factor signaling in the development and maintenance of human T cell memory. Immunity 35, 806–818 (2011).
Durant, L. et al. Diverse targets of the transcription factor STAT3 contribute to T cell pathogenicity and homeostasis. Immunity 32, 605–615 (2010).
Butler, M.O. et al. Ex vivo expansion of human CD8+ T cells using autologous CD4+ T cell help. PLoS One 7, e30229 (2012).
Jedema, I., van der Werff, N.M., Barge, R.M., Willemze, R. & Falkenburg, J.H. New CFSE-based assay to determine susceptibility to lysis by cytotoxic T cells of leukemic precursor cells within a heterogeneous target cell population. Blood 103, 2677–2682 (2004).